Deliver Your News to the World

CybeRelease: (OTC: CSBF) Reports Letter of Intent for Equity Investment


(CybeRelease, October 18, 2006) - Lake Harmony, PA - Consolidated Biofuels, Inc. (OTC PK: CSBF), an alternative fuels company, announced, through its CEO, Daniel Honeycutt, that: “We have recently executed a Letter of Intent with International Bio Fuels Corporation, a private company headquartered in Vancouver, Washington, that will, when formalized, provide a substantial equity investment by International into Consolidated.”

Mr. Honeycutt further stated that: “I am very pleased, for the Company and for its shareholders, that, after many weeks of concentrated review, International has made a positive decision to make this very significant, albeit preliminary, commitment of equity investment into Consolidated.”

International’s President, Mr. Marty Johnson, stated “We have looked at almost every public company in the biodiesel industry and believe that Consolidated’s business strategy, particularly its feedstock sourcing, technology and international focus, line up very well with our own. I think Daniel is correct when he says that, ’Consolidated is at the right place, at the right time, and with the right team.’ We look forward to partnering with Consolidated on many levels within the biofuels industry, and also to supporting their efforts with our financial resources, advanced technology solutions and plant construction expertise.”

Further details of this particular transaction will be announced after professional advisors for both companies have completed their productions and a formal Agreement has been executed by both parties.

To read the complete release, go to

CybeRelease Gainers are Broadwing Corporation (Nasdaq: BWNG), Lumera Corporation (Nasdaq: LMRA), ICOS Corporation (Nasdaq: ICOS), Pemstar Inc. (Nasdaq: PMTR), StemCells, Inc. (Nasdaq: STEM), Discovery Laboratories, Inc. (Nasdaq: DSCO), Superconductor Technologies Inc. (Nasdaq: SCON) and Parlux Fragrances, Inc. (Nasdaq: PARL).

CybeRelease Decliners are Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), Cognex Corporation (Nasdaq: CGNX), Linear Technology Corporation (Nasdaq: LLTC), Novellus Systems, Inc. (Nasdaq: NVLS), RF Micro Devices, Inc. (Nasdaq: RFMD), Generex Biotechnology Corporation (Nasdaq: GNBT), Sapient Corporation (Nasdaq: SAPE) and ADTRAN, Inc. (Nasdaq: ADTN).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. The company has hired and paid $995.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.